|
1
|
Hallek M, Bergsagel PL and Anderson KC:
Multiple myeloma: Increasing evidence for a multistep
transformation process. Blood. 91:3–21. 1998.PubMed/NCBI
|
|
2
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raab MS, Podar K, Breitkreutz I,
Richardson PG and Anderson KC: Multiple myeloma. Lancet.
374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy
MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust
JA, et al: Improved survival in multiple myeloma and the impact of
novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar
|
|
5
|
Laubach J, Richardson P and Anderson K:
Multiple myeloma. Annu Rev Med. 62:249–264. 2011. View Article : Google Scholar
|
|
6
|
Mahindra A, Laubach J, Raje N, Munshi N,
Richardson PG and Anderson K: Latest advances and current
challenges in the treatment of multiple myeloma. Nat Rev Clin
Oncol. 9:135–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ling YH, Jiang JD, Holland JF and
Perez-Soler R: Arsenic trioxide produces polymerization of
microtubules and mitotic arrest before apoptosis in human tumor
cell lines. Mol Pharmacol. 62:529–538. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uslu R, Sanli UA, Sezgin C, Karabulut B,
Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated
cytotoxicity and apoptosis in prostate and ovarian carcinoma cell
lines. Clin Cancer Res. 6:4957–4964. 2000.
|
|
9
|
Zhang TC, Cao EH, Li JF, Ma W and Qin JF:
Induction of apoptosis and inhibition of human gastric cancer
MGC-803 cell growth by arsenic trioxide. Eur J Cancer.
35:1258–1263. 1999. View Article : Google Scholar
|
|
10
|
Litzow MR: Arsenic trioxide. Expert Opin
Pharmacother. 9:1773–1785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Phatak P, Dai F, Butler M, Nandakumar MP,
Gutierrez PL, Edelman MJ, Hendriks H and Burger AM: KML001
cytotoxic activity is associated with its binding to telomeric
sequences and telomere erosion in prostate cancer cells. Clin
Cancer Res. 14:4593–4602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Woo SR, Ham Y, Kang W, Yang H, Kim S, Jin
J, Joo KM and Nam DH: KML001, a telomere-targeting drug, sensitizes
glioblastoma cells to temozolomide chemotherapy and radiotherapy
through DNA damage and apoptosis. BioMed Res Int. 2014:7474152014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang MH, Kim HT, Lee KT, Yang S, Lee JK,
Lee KH and Rhee JC: KML001 inhibits cell proliferation and invasion
in pancreatic cancer cells through suppression of NF-κB and VEGF-C.
Anticancer Res. 34:3469–3474. 2014.PubMed/NCBI
|
|
14
|
Yoon JS, Hwang DW, Kim ES, Kim JS, Kim S,
Chung HJ, Lee SK, Yi JH, Uhm J, Won YW, et al: Anti-tumoral effect
of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's
lymphoma: An in vitro and in vivo study. Invest New Drugs. 34:1–14.
2016. View Article : Google Scholar
|
|
15
|
d'Adda di Fagagna F, Reaper PM,
Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G,
Carter NP and Jackson SP: A DNA damage checkpoint response in
telomere-initiated senescence. Nature. 426:194–198. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartek J and Lukas J: DNA damage
checkpoints: From initiation to recovery or adaptation. Curr Opin
Cell Biol. 19:238–245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jazayeri A, Falck J, Lukas C, Bartek J,
Smith GC, Lukas J and Jackson SP: ATM- and cell cycle-dependent
regulation of ATR in response to DNA double-strand breaks. Nat Cell
Biol. 8:37–45. 2006. View
Article : Google Scholar
|
|
19
|
Zhang B, Suer S, Livak F, Adediran S,
Vemula A, Khan MA, Ning Y and Hussain A: Telomere and microtubule
targeting in treatment-sensitive and treatment-resistant human
prostate cancer cells. Mol Pharmacol. 82:310–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thornberry NA and Lazebnik Y: Caspases:
Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoon JS, Kim ES, Park BB, Choi JH, Won YW,
Kim S and Lee YY: Anti-leukemic effect of sodium metaarsenite
(KML001) in acute myeloid leukemia with breaking-down the
resistance of cytosine arabinoside. Int J Oncol. 46:1953–1962.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blackburn EH: Telomeres and telomerase:
Their mechanisms of action and the effects of altering their
functions. FEBS Lett. 579:859–862. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moyzis RK, Buckingham JM, Cram LS, Dani M,
Deaven LL, Jones MD, Meyne J, Ratliff RL and Wu JR: A highly
conserved repetitive DNA sequence, (TTAGGG)n, present at the
telomeres of human chromosomes. Proc Natl Acad Sci USA.
85:6622–6626. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Masutomi K, Yu EY, Khurts S, Ben-Porath I,
Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, DeCaprio JA,
et al: Telomerase maintains telomere structure in normal human
cells. Cell. 114:241–253. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shay JW and Gazdar AF: Telomerase in the
early detection of cancer. J Clin Pathol. 50:106–109. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chou WC, Hawkins AL, Barrett JF, Griffin
CA and Dang CV: Arsenic inhibition of telomerase transcription
leads to genetic instability. J Clin Invest. 108:1541–1547. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang ES, Wu K, Chin AC, Chen-Kiang S,
Pongracz K, Gryaznov S and Moore MA: Telomerase inhibition with an
oligonucleotide telomerase template antagonist: In vitro and in
vivo studies in multiple myeloma and lymphoma. Blood. 103:258–266.
2004. View Article : Google Scholar
|
